ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

Breast Cancer

70-Gene Signature Could Help Early-Stage Breast Cancer Patients Avoid Chemotherapy

Using a 70-gene signature test could identify many women with early-stage breast cancer considered to be at high clinical risk who do not actually need chemotherapy. Image © anyaivanova / Shutterstock.com.

Breast Cancer

Combining a genetically engineered epothilone analog known as utidelone with capecitabine significantly improved progression-free survival in women with metastatic breast cancer who were refractory to anthracycline and taxane regimens.

We know that breast cancer represents a spectrum of diseases, with variation in prognosis, and that RT can range from highly complex treatments to the breast and regional lymph nodes, to complete avoidance of radiation.

To paraphrase a deep philosophical question: if an important, long-awaited phase III prospective randomized trial from Europe is published and no one pays attention, does it make a sound?

Relatively few clinically important therapeutic advances have occurred in the treatment of triple-negative breast cancer since the introduction of taxanes as adjuvant therapy over 20 years ago. However, this is rapidly changing due to a variety of conceptually important clinical trials and emerging new options.

A phase I trial found that ONT-380 had a lower incidence of certain adverse events associated with this class of agent and notable anti-tumor activity in heavily pretreated metastatic HER2-positive breast cancer patients.

A large registry study found that certain breast cancer patients gain a significant survival benefit with breast conserving surgery plus radiation therapy compared with mastectomy.

Residual cancer burden was found to be prognostic for long-term survival following neoadjuvant chemotherapy for three phenotypic subsets of breast cancer in a new single-institution study.

Pages

Subscribe to Breast Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.